A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs

NCT01353859 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: tocilizumab [RoActemra/Actemra]
DRUG: methotrexate

Sponsor

Hoffmann-La Roche